Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations

  title={Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations},
  author={Jean Yves Blay and Peter Reichardt},
  journal={Expert Review of Anticancer Therapy},
  pages={831 - 838}
The European Society for Medical Oncology (ESMO) recommendations on the management of gastrointestinal stromal tumor (GIST) have recently been updated. Imatinib 400 mg/day remains the standard first-line treatment for patients with metastatic GIST. Mutational analysis has received a strong recommendation for diagnostic purposes. Furthermore, patients with KIT exon 9-activating mutations are now recommended to receive imatinib 800 mg/day as first-line treatment. Following progression during… 

Gastrointestinal Stromal Tumors: Clinicopathology and Advances in Molecular Pathogenesis

Advances in understanding the molecular nature of GISTs also provide valuable therapeutic targets, and two tyrosine kinase inhibitors, Imatinib and Sunitinib, have currently been approved for treating patients with advanced and metastatic Gists.

Soft tissue sarcomas & GIST Insights into subtype-specific therapy concepts: Highlights from ASCO meeting 2015

This review covers the latest clinical study highlights for STS and GIST presented at ASCO 2015 meeting, demonstrating the constant progress from conventional chemotherapy to histology-driven therapy approaches.

Gastrointestinal stromal tumours at present: an approach to burning questions.

This article focuses on what it considers to be hot spots in GIST at present, and a final summary of recommendations and a management algorithm are included.

Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor

  • P. ChiL. Qin W. Tap
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2022
The combination of imatinib and binimetinib is effective with manageable toxicity and warrants further evaluation in direct comparison withImatinib in frontline treatment of GIST, which met the primary end point.

Molecular characterisation of gastrointestinal stromal tumours in a South African population.

The incidence of mutations in KIT exon 11 and PDGFRα exon 18 is consistent with the literature, however, the low incidence of KITExon 9 mutations detected was unexpected, indicating this mutation appears to be rare in the South African population.

Oral pigmentation in the hard palate associated with imatinib mesylate therapy: a report of three cases.

A Case of Gastrointestinal Stromal Tumor with Recurrent Hypoglycemia

Non-islet cell tumor induced hypoglycemia (NICTH) is attributable to overproduction of insulin-like growth factor-II (IGF-II) by solid tumors, and these tumors usually originate from mesenchymal or

Getting the gist: what is the importance of molecular genetics in gastro-intestinal stromal tumours (GIST).

The treatment of GIST patients has drastically changed since the introduction of tyrosine kinase inhibitors (TKI), such as Imatinib mesylate, which targets KIT and PDGFRa.

Soft tissue sarcoma: from molecular diagnosis to selection of treatment. Pathological diagnosis of soft tissue sarcoma amid molecular biology and targeted therapies.

An overview of the most important genomic aberrations in sarcomas, their differential diagnosis and the relevance of molecular biology for treatment strategies is given.



Gastrointestinal stromal tumor: 5 years later

The integration of surgery and molecular therapy in GIST will serve as a prototype for the management of other solid tumors for which targeted agents become available.

Combining imatinib with surgery in gastrointestinal stromal tumors: rationale and ongoing trials.

The rationale for combining imatinib with surgery for GIST, either as an adjuvant agent in the situation of primary resection for patients at high risk or in the neoadjuvant setting for patients with locally advanced, recurrent, or metastatic disease, is compelling in the continuous effort to improve disease-free and overall survival.

Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up.

Gastrointestinal stromal tumors: ESMO Clinical Recommendations for diagnosis, treatment and follow-up P. G. Casali, L. Jost, P. Reichardt, M. Schlemmer & J.-Y. Blay On behalf of the ESMO Guidelines

Biology of gastrointestinal stromal tumors.

The rapid progress that has established GIST as a model for understanding the role of oncogenic kinase mutations in human tumorigenesis is charted and a molecular-based classification of GIST is proposed.

Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate.

A nodule within a mass is an important sign of recurrent GIST, but measurements of overall tumor size may not enable detection of such nodules.

Response evaluation of gastrointestinal stromal tumors.

Modified CT criteria using a combination of tumor density and tumor size are promising in early response evaluation, and have excellent prognostic value.

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor, indicating that inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinalStromal tumors, which resist conventional chemotherapy.

Assessing the prognosis of gastrointestinal stromal tumors: a growing role for molecular testing.

  • C. Corless
  • Medicine
    American journal of clinical pathology
  • 2004
This important study, the first in the post-KIT era, confirms 2 general observations about GISTs: (1) the great majority of very-low-risk, low- risk, and intermediate-risk Gists behave in a benign manner, and (2) among these tumors, there is an unpredictable subset that behaves aggressively.